Formycon AG — Board/Management Information 2013

Nov 4, 2013

News Details

Corporate | 4 November 2013 08:15

Formycon AG today has announced the appointment of Gerhard Schaefer and Simon Sturge to Formycon’s Advisory Board

Formycon AG / Key word(s): Change of Personnel

04.11.2013 08:15

Dissemination of a Corporate News, transmitted by DGAP - a company of EQS
Group AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Munich - Both members of the newly implemented Advisory Board are very
experienced senior healthcare executives who have contributed during their
long careers substantially to the development of the global generic
pharmaceutical and biopharmaceutical industry.

The Advisory Board will advise Formycon's Executive Management Board and
the Supervisory Board on strategic issues, operational aspects and growth
opportunities related to Formycon's business activities.

Gerhard Schaefer is German Citizen and graduated with a Ph.D. in Chemistry
from Stuttgart University. During his more than 30 years in the generic
pharmaceutical industry, he held increasing senior management positions in
development, quality assurance / control and business development at
Azupharma, Knoll, Stada, HEXAL and Sandoz. Among his numerous
responsibilities, he was appointed to Head of Development and Business
Development at HEXAL in 2001 and at the same time became Member of the
Board of Executive Directors of HEXAL AG. Since the acquisition of HEXAL AG
by Novartis / Sandoz in 2005 and until February 2012, he was Managing
Director at Sandoz International and Head of Global Product Development and
Global Business Development at Sandoz, the second largest generic
pharmaceutical company, where he was managing eleven development centers
worldwide.

Simon Sturge is citizen of the United Kingdom and holds a degree in Biology
from Sussex University. He has over 30 years of experience in the
pharmaceutical and biotech industries. Until recently, he was Corporate
Senior Vice President of Biopharmaceuticals at Boehringer Ingelheim (BI), a
top-20 pharmaceutical company, and among the world largest
biopharmaceutical enterprises. At BI he was responsible for the
biopharmaceutical business unit which has approximately 2,200 employees.
From 2008-2010 he was Chief Executive of OctoPlus, a Dutch-based listed
biopharmaceutical company. In 1997 he founded RiboTargets, which in 2003
reversed into British Biotech, where he was also Chief Executive Officer.
British Biotech was renamed Vernalis and he remained Chief Executive until
2008. Prior to this Simon Sturge was at Celltech for 10 years where he was
also on the Celltech Group Board, before he became Chief Executive Officer
at Lonza Biologics.

Formycon's CFO Nicolas Combé said: 'I would like to welcome Mr. Schaefer
and Mr. Sturge to our Advisory Board. The Board will play an important role
in our plans to create a world-class organization in biopharmaceutical and
biosimilar development and commerzialization.'

Formycon's CEO Carsten Brockmeyer said: 'I am excited about these excellent
appointments. Mr. Schaefer and Mr. Sturge will bring a breadth of
experience to the company. Their expertise in a wide range of fields will
be invaluable in driving forward Formycon's business objectives.'

About Formycon:
Formycon AG is a biopharmaceutical company with more than ten years of
product development experience spanning the entire pharmaceutical value
creation chain all the way through to phase III clinical trials and
registration. The company's business focus is on the development of
biopharmaceuticals, particularly global quality biosimilars, as well as the
creation of innovative forms of drug delivery, both for use in its own
products as well as on a service-provider basis for other biotechnology and
pharmaceutical companies. Formycon's success in developing global quality
biosimilars depends critically upon the fulfillment of all requirements for
regulatory approval. To achieve this as quickly and efficiently as
possible, the company's experts in protein analysis, cell line and process
development, product development, quality control, clinical trials and
regulatory affairs work closely together as an integrated development team.
The expected rapid growth of the global market for biosimilars presents a
significant opportunity for Formycon AG.

Contact:
Formycon AG
Fraunhoferstr. 15
82152 Martinsried/Planegg (Germany)
phone +49 (0) 89 - 86 46 67 100
ir@formycon.com // www.formycon.com

Disclaimer:
This release may contain forward-looking statements and information which
may be identified by formulations using terms such as 'expects', 'aims',
'anticipates', 'intends', 'plans', 'believes', 'seeks', 'estimates' or
'will'. Such forward-looking statements are based on our current
expectations and certain assumptions which may be subject to variety of
risks and uncertainties. The results actually achieved by Formycon AG may
substantially differ from these forward-looking statements. Formycon AG
assumes no obligation to update these forward-looking statements or to
correct them in case of developments which differ from those anticipated.

04.11.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Formycon AG
Fraunhoferstraße 145
82152 Planegg-Martinsried
Germany
Phone: 089 864667 100
Fax: 089 864667 110
E-mail:
Internet: www.formycon.com
ISIN: DE000A1EWVY8
WKN: A1EWVY
Listed: Freiverkehr in Berlin; Frankfurt in Open Market (Entry
Standard)

End of Announcement DGAP News-Service

---